Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.
Fiche publication
Date publication
septembre 2017
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc
Tous les auteurs :
Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X
Lien Pubmed
Résumé
Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell responses against tumor associated antigens (TAA) targeted by the vaccine.
Mots clés
Cancer vaccine, Lung cancer, T cell response, Tumor associated antigen, Viral vaccine
Référence
J Immunother Cancer. 2017 Sep;5(1):70